{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:24:00Z","timestamp":1782923040586,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116826","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T15:44:01Z","timestamp":1779551041000},"page":"116826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0057-2424","authenticated-orcid":false,"given":"Shiori","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5572-1337","authenticated-orcid":false,"given":"Kota","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4482-6210","authenticated-orcid":false,"given":"Shonosuke","family":"Wakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8130-6815","authenticated-orcid":false,"given":"Shunsuke","family":"Oyamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6480-4799","authenticated-orcid":false,"given":"Tomoyuki","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Numakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakura","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2502-3666","authenticated-orcid":false,"given":"Keigo","family":"Komine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Saijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Shirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-4850","authenticated-orcid":false,"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116826_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4143\/crt.2014.308","article-title":"Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review","volume":"47","author":"Park","year":"2015","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2026.116826_bib2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.gastha.2023.01.009","article-title":"Treatment patterns and survival in locally advanced or metastatic biliary tract cancer using SEER medicare data","volume":"2","author":"Danese","year":"2023","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.ejca.2026.116826_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116826_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2026.116826_bib5","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116826_bib6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines(R) insights: biliary tract cancers, Version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2026.116826_bib7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2026.116826_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.988527","article-title":"Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: a prospective multicenter study","volume":"12","author":"Takada","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116826_bib9","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1007\/s10147-024-02616-x","article-title":"Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer","volume":"29","author":"Inada","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116826_bib10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s11523-023-00985-3","article-title":"A retrospective analysis of biliary tract cancer patients presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich","volume":"18","author":"Zhang","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2026.116826_bib11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.ejca.2026.116826_bib12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2026.116826_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2026.116826_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216766","article-title":"Potential role of p53 deregulation in modulating immune responses in human malignancies: a paradigm to develop immunotherapy","volume":"588","author":"Chauhan","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejca.2026.116826_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.celrep.2019.12.028","article-title":"Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses","volume":"30","author":"Blagih","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2026.116826_bib16","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116826_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1200\/JCO.2019.37.8_suppl.53","article-title":"Investigating the tumor-immune microenvironment in an autochthonous murine model of cholangiocarcinoma","volume":"37","author":"Han","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116826_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.ejca.2026.116826_bib19","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jnci\/djad046","article-title":"Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma","volume":"115","author":"Spencer","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116826_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051454","article-title":"Extrahepatic distal cholangiocarcinoma vs. pancreatic ductal adenocarcinoma: histology and molecular profiling for differential diagnosis and treatment","volume":"15","author":"Gkountakos","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116826_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41698-025-01087-1","article-title":"Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis","volume":"9","author":"Jiang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116826_bib22","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1245\/s10434-023-13383-w","article-title":"Sintilimab plus modified FOLFIRINOX in metastatic or recurrent pancreatic cancer: the randomized phase II CISPD3 trial","volume":"30","author":"Fu","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116826_bib23","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116826_bib24","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/jnci\/djaf155","article-title":"The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population","volume":"117","author":"Rimini","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116826_bib25","article-title":"86P Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study","volume":"33","author":"He","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116826_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105306","article-title":"Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers","volume":"10","author":"Iida","year":"2025","journal-title":"ESMO Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:56:32Z","timestamp":1781153792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"alternative-id":["S0959804926006076"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116826","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116826"}}